Your session is about to expire
← Back to Search
BRAF-Targeted Therapy for Colon Cancer
Study Summary
This trial compares encorafenib + cetuximab (which may stop tumor growth) to usual care for reducing colon cancer recurrence after standard surgery + chemo.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My tumor is microsatellite stable.I don't have any severe health issues like uncontrolled infections or heart disease.My blood pressure is under control.My heart function is classified as class 2B or better, despite my history of cardiac issues or treatments.My cancer's BRAF V600 status has been or will be tested.I've completed at least 3 months of specific chemotherapy for my cancer.I am not taking medications that can cause heart rhythm problems.I have no active cancer except for non-dangerous skin cancer or treated cervical cancer.I have not received any treatments for my current colon cancer.I am not taking strong CYP3A4 inducers, or I can stop them 14 days before the study starts.My cancer is at stage III or high-risk stage II.My cancer is located in the colon.I am HIV positive, on treatment, and my viral load has been undetectable for the last 6 months.I am 18 years old or older.I am able to care for myself and perform daily activities.I can swallow pills without any medical issues.My cancer has the BRAF V600E mutation.My colon cancer is stage III or high-risk stage II and was completely removed.My cancer is not active if it was a small carcinoid, non-invasive breast or endometrial cancer.I am not taking strong CYP3A4 inhibitors, or can stop them 14 days before the study.I finished my additional cancer treatment less than 8 weeks ago.I don't have lasting side effects from past chemotherapy, except for possible hair loss or nerve pain.I am not pregnant or breastfeeding and, if capable of bearing children, have a recent negative pregnancy test.My kidney function, measured by creatinine clearance, is good.I had a noninvasive skin cancer that is not currently active.
- Group 1: Arm I (encorafenib, cetuximab)
- Group 2: Arm II (patient observation)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many locations in the state are actively conducting this research?
"This experiment is presently being conducted at 55 different centres, scattered across Canton, Carthage and Decatur as well as other cities. It would be beneficial for participants to choose the closest site to minimize travel requirements when they enroll in this trial."
Is this medical experiment currently recruiting participants?
"Indeed, current records on clinicaltrials.gov show that this medical trial is open for enrollment. The experiment was first posted in May 30th 2023 and has been revised recently on August 2nd 2023 with the aim of recruiting 394 volunteers across 55 sites worldwide."
What is the projected enrollment of this trial?
"Affirmative, data available on clinicaltrials.gov reveals that this trial is currently seeking out participants. It was initially posted online on 30th May 2023 and last modified on 2nd August 2023. Participants are being recruited from 55 medical centers with a total of 394 people required for the study."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger